Filing Flows › Biodesix (BDSX) › Q2 2025
Biodesix (BDSX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Biodesix (BDSX) reported revenue of $20.0M for the second quarter 2025 (Q2 2025), +12% from a year earlier and +11% from the quarter before. Operating margin was -48.6%, net loss $11.5M (57.3% of revenue).
Biodesix, Q2 2025: revenue $20.0M (+12% year over year), operating margin -48.6%, net loss $11.5M, operating cash flow −$6.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.0M | +11% | +12% |
| Operating profit | −$9.7M | — | — |
| Net earnings | −$11.5M | — | — |
| Operating cash flow | −$6.6M | — | — |
What changed
Revenue was $20.0M in Q2 2025, up 12% year over year and up 11% from the previous quarter. Diagnostic Tests was the largest line at 89% of revenue. Diagnostic Tests added $1.4M year over year (up 8%), 65% of the total change.
Operating costs exceeded revenue by $9.7M, an operating margin of -48.6%. Total costs grew 14% against revenue growth of 12%. The fastest-growing cost line was Research & development (+28%). The quarter ended with a net loss of $11.5M, wider than the previous quarter's $11.1M loss.
Operating cash flow was −$6.6M. Non-cash charges added back $1.4M of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items added $2.4M. Capital expenditures of $51K exceeded it, leaving free cash flow of −$6.6M.
Questions
What was Biodesix's revenue in the second quarter 2025?
Biodesix (BDSX) reported revenue of $20.0M for the second quarter 2025 (Q2 2025), +12% from a year earlier and +11% from the quarter before.
Was Biodesix profitable in the second quarter 2025?
Operating loss was $9.7M (-48.6% of revenue) and net loss $11.5M.
Source: Biodesix 10-Q on SEC EDGAR.